Skip to main content

UNC Lineberger members will be presenting research findings, providing commentary and leading education sessions at the American Society of Clinical Oncology’s 58th annual meeting at McCormick Place in Chicago, June 3-7.

The world’s largest clinical cancer research meeting, ASCO’s annual meeting is attended by more than 30,000 oncology professionals from around the world and this year will feature more than 2,500 presentations.

Some of the presentations made by UNC Lineberger and UNC faculty and trainees include:

Saturday, June 4

Oral Presentations

Breast Cancer – Metastatic

1:15 – 4:15 p.m.  CT |  Hall D1

Local Therapy for Metastatic Breast Cancer in a Rapidly Evolving Treatment Landscape: What Comes Next?

Gaorav P. Gupta, MD, PhD

3:51 – 4:03 p.m. CT

Poster Discussion

Professional Development and Education Advances

4:30 – 6 p.m. CT  |  S504

11004 – Seeking racial equity in hematology and oncology: A fellow-led educational series to promote reflection and action

Jacob Newton Stein, MD, Jacquelyne Janean Gaddy, Jonathan D Sorah, Melissa Wooten, Keisha Gibson, Frances A. Collichio, MD  (Poster 109)

Genitourinary Cancer – Kidney and Bladder

4:30 – 6 p.m.  CT |  Arie Crown Room

Improving Outcomes Across the Stages in Bladder Cancer

Discussant: Matthew I. Milowsky, MD

5:14 – 5:26 p.m. CT

Poster Session

12037 – The impact of diabetes on the performance of skeletal muscle density (SMD) in screening for frailty: Findings from the Cancer and Aging Resilience Evaluation (CARE) Registry

Sydney T. Thai (Poster 283)

12109 – A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer

Zev Nakamura, MD (Poster 353)

Oncology Division Chiefs & Department Chairs’ Breakfast

7:30 – 9:30 a.m.  |  S103

Ethan Basch, MD, MSc, FASCO

Sunday, June 5

Poster Session

Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

8 – 11 a.m. CT |  Hall A

3053 – Prospective characterization of circulating tumor cell kinetics in patients treated with radiation therapy per definitive intent oligometastatic paradigm

Shivani Sud, MD (Poster 45)

Education Session

The Spectrum of Clinical Evidence: Real-World Data to Clinical Trials

9:45 – 11 a.m. CT |  S404

Real-World Data: Promises and Pitfalls in Turning Data to Evidence

Jennifer Lund, PhD

10:09 – 10:21 a.m. CT

ASCO Plenary Series

Rapid Abstract Updates

4:30 – 6 p.m. CT |  Arie Crown Theater

Updates on Abstract 349527: Digital symptom monitoring with patient-reported outcomes in community oncology practices: A U.S. national cluster randomized trial

Ethan Basch, MD, MSc, FASCO

4:36 – 4:42 p.m. CT

Meet the Professors

Moving Beyond Routine Assessments of Older Adults With Cancer – Biomarkers, Geriatric Assessment, or Both?

8 – 9:15 a.m. CT  |  E253D

Geriatric Assessment: Prognosticator, Predictor, and Actionable

Shakira Grant, MBBS

8:20 – 8:40 a.m. CT

Monday, June 6

Oral Abstract Session

Primary Track: Gastrointestinal Cancer – Colorectal and Anal

9:45 a.m. – 12:45 p.m. CT |  Arie Crown Theater

Optimizing Multidisciplinary Care for Patients With Early-Stage Colorectal Cancer

Discussant: Karyn Stitzenberg, MD, MPH

10:21 – 10:33 a.m. CT

Poster Discussion

Breast Cancer – Local/Regional/Adjuvant

1:15 – 2:45 p.m. CT | Hall B1

509 – Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.

Aranzazu Fernandez-Martinez, MBBS (Poster 281)

Poster Session

Health Services Research and Quality Improvement

1:15 – 4:15 p.m. CT | Hall A

6586 – Time at home among older adults with acute myeloid leukemia based on treatment intensity: A SEER-Medicare analysis

Daniel R. Richardson, MD, MSc, MA (Poster 368)

Head and Neck Cancer

1:15 – 4:15 p.m. CT | Hall A

6041 – PDS0101, a novel type I interferon and CD8 T-cell activating immunotherapy, in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)

Jared Weiss, MD (Poster 33)